New AI Model Fuses Sequence and Structure Data to Sharpen Drug-Target Interaction Prediction

Finding the right drug for the right molecular target remains one of the slowest and most expensive steps in modern drug discovery, and a new deep learning framework published in BMC Bioinformatics aims to accelerate that search by teaching artificial intelligence to read drugs and proteins in two complementary languages at once. The model, called DHF-DTI, was developed by a team at Foshan University in China and is designed to predict drug-target interactions, the fundamental molecular handshakes that determine whether a compound will bind to a protein and produce a therapeutic effect.

Drug-target interaction prediction is a cornerstone of computational pharmacology. When researchers screen a new molecule, they need to know which proteins it might latch onto, because those binding events define both the intended benefit and the potential side effects of a drug. Experimentally testing every possible pairing is prohibitively slow, so computational models that can reliably rank which interactions are likely have become essential tools for shortening development cycles and cutting costs. Deep learning has made remarkable progress in this arena, but the authors of the new study argue that existing approaches leave significant information on the table.

The central problem the team identified is that drugs and proteins can be represented in fundamentally different ways. On one side sits sequence data: the linear string of amino acids in a protein, or the chemical notation describing a drug molecule. On the other side sits graph structure data, which encodes how atoms in a molecule are connected and how residues in a protein relate to one another spatially. Each representation captures different aspects of molecular identity, and most prior models struggle to fully exploit the complementary information between these modalities when handling multimodal data, according to the study.

DHF-DTI tackles this challenge with a purpose-built component called the Cross-Attention and Bilinear Fusion Module, abbreviated CABFusion. Cross-attention is a mechanism borrowed from modern transformer architectures that allows one data stream to selectively focus on the most informative parts of another. In practice, this means the model can align features from a drug’s chemical graph with the relevant segments of a protein’s sequence, achieving fine-grained fusion of local features while simultaneously capturing global contextual dependencies that span the entire molecule. The bilinear component of the module then multiplies feature representations together, letting the network model rich, higher-order interactions between the two modalities rather than simply concatenating them.

The second innovation addresses a subtler but equally important weakness in existing models. Most drug-target predictors are trained purely with classification loss, which teaches the network to output a binding probability but says little about how the learned internal representations are organized. The Foshan team found that relying solely on classification loss makes it difficult to learn highly discriminative feature representations in the latent space, which severely limits the robustness and domain generalization ability of the model. In other words, a model might perform well on familiar data but falter when asked to evaluate a drug or protein it has never seen before.

To fix this, the researchers introduced supervised contrastive learning into the training pipeline. This technique reshapes the geometry of the model’s internal feature space by pulling together representations of interacting drug-protein pairs while pushing apart non-interacting ones. The result is a latent space in which true interactions form tight, well-separated clusters, improving both inter-class separability and generalization. This matters enormously in real-world drug discovery, where the molecules of greatest interest are often precisely the ones least represented in existing databases.

The team evaluated DHF-DTI across three increasingly demanding testing regimes: intra-domain, cross-domain, and cold-start scenarios. Intra-domain testing measures performance when training and test data come from the same distribution, the easiest setting. Cross-domain evaluation probes whether the model transfers knowledge between different datasets or biological contexts. Cold-start scenarios are the harshest test of all, asking the model to make predictions for drugs or targets that were entirely absent from its training data. Across all three regimes, the study reports that DHF-DTI significantly outperformed state-of-the-art methods in both prediction performance and generalization, a combination that suggests the dual-modality fusion strategy is capturing genuinely useful molecular information rather than exploiting dataset artifacts.

Beyond raw benchmark numbers, the authors conducted case studies, drug feature visualization, and error analysis to validate the model’s application potential in practical drug discovery. Feature visualization allows researchers to inspect how the network organizes drug representations in its latent space, offering a window into whether the learned structure aligns with known pharmacological relationships. Error analysis, meanwhile, examines the cases where the model fails, providing insight into the remaining gaps between computational prediction and biological reality. This kind of transparency is increasingly seen as essential for models intended to guide laboratory experiments rather than merely top leaderboards.

The implications for the pharmaceutical industry could be substantial. A model that generalizes well to unseen drugs and targets can help prioritize which compounds advance to expensive wet-lab validation, potentially saving years of trial-and-error screening. The work also reflects a broader trend in computational biology: the recognition that no single data representation is sufficient, and that hybrid architectures capable of fusing sequence, structure, and other modalities are becoming the new standard for molecular machine learning. As multimodal approaches mature, they are expected to underpin more efficient and accurate drug discovery pipelines from target identification through lead optimization.

The research, led by Dongjie Chen with corresponding authors Zhihui Yang and Mingming Zhao, was supported by funding from the Basic and Applied Basic Research program of Guangdong Province, the Medical Science and Technology Research program of Guangdong Province, the Science and Technology Innovation Project of Foshan City, the National Natural Science Foundation of China, and the Guangdong Provincial Overseas Distinguished Scholar Program. The full study is available as an open-access article in BMC Bioinformatics, allowing researchers worldwide to examine, reproduce, and build upon the framework as the field moves toward more robust and generalizable models of molecular interaction.

Subject of Research: DHF-DTI: a dual-modality hybrid fusion framework for drug-target interaction prediction

Article Title: DHF-DTI: a dual-modality hybrid fusion framework for drug-target interaction prediction

Article References: Chen, D., Liu, Y., Yi, Y., Liu, Z., Zhang, R., Liu, D., Yang, Z., & Zhao, M. (2026). DHF-DTI: a dual-modality hybrid fusion framework for drug-target interaction prediction. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06673-z

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06673-z

Keywords: drug-target interaction, deep learning, multimodal fusion, supervised contrastive learning, drug discovery, cross-attention, BMC Bioinformatics, machine learning, computational pharmacology, cold-start prediction, DHF-DTI, dual-modality